Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 2018 May 21, 2018 05:44AM
Chugai's HEMLIBRA® Receives Breakthrough Therapy Designation from U.S. FDA for Hemophilia A Without Factor VIII Inhibitors Apr 17, 2018 01:00AM
Chugai's HEMLIBRA® Approved by European Commission in Hemophilia A with Inhibitors Feb 27, 2018 09:20PM
Chugai's HEMLIBRA® Gains Positive CHMP Opinion in Hemophilia A with Inhibitors Jan 28, 2018 06:30PM
EU Follows US and Approves Chugai's ALK Inhibitor "Alecensa®" as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer Dec 21, 2017 01:30AM